Open AccessAlendronate inhibits cell invasion and MMP‐2 secretion in human chondrosarcoma cell line 1
Author(s) -
LAI Tejen,
HSU Shengfeng,
LI Temao,
HSU Horngchaung,
LIN Jaunggeng,
HSU Chinjung,
CHOU Mingchih,
LEE Mengchih,
YANG Shunfa,
FONG Yichin
Publication year - 2007
Publication title -
acta pharmacologica sinica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.514
H-Index - 90
eISSN - 1745-7254
pISSN - 1671-4083
DOI - 10.1111/j.1745-7254.2007.00607.x
Subject(s) - chondrosarcoma , matrix metalloproteinase , bisphosphonate , gentamicin protection assay , zymography , cancer research , cell culture , secretion , matrigel , chemotherapy , osteosarcoma , medicine , pathology , chemistry , biology , metastasis , cancer , osteoporosis , angiogenesis , genetics
Aim: Chondrosarcoma is a malignant primary bone tumor that responds poorly to both chemotherapy and radiation therapy. The aim of the present study was to investigate the effect of alendronate, a bisphosphonate, on the invasion and migration of human chondrosarcoma cells (JJ012). Methods: JJ012 cells were treated with alendronate of various concentrations up to 100 μmol/L for a specified period, and then gelatin zymography and matrigel invasion assay was performed to study the effects of alendronate on matrix metalloproteinase (MMP)‐2 activity and the invasion ability of JJ012 cells, respectively. Results: Our data showed that alendronate exerted a dose‐ and time‐dependent inhibitory effect on the invasion and migration of JJ012 cells. Furthermore, gelatin zymography and RT‐PCR showed that alendronate treatment decreased the activity and mRNA levels of MMP‐2 in a concentration‐dependent manner. Conclusion: Our findings suggest that alendronate may reduce MMP‐2 secretion at the transcriptional and translational levels, and inhibit the invasion of chondrosarcoma cell. Therefore, alendronate may be a potential candidate for the systemic therapy of chondro‐sarcomas, as well as other malignant diseases.